Class 2 drug alert, action within 48 hours, patient level recall, ceska republika s.r.o. (an affiliate of bausch and lomb uk limited), Emerade 150 micrograms solution for injection in pre-filled syringe

Manufacturers are recalling all unexpired batches of Emerade 150 microgram auto-injectors from patients due to an error in one component of the auto-injector believed to cause some pens to fail to activate and deliver adrenaline.

SPS commentary:

Healthcare professionals (GP Practices, Pharmacies) should, contact patients and carers with Emerade 150mcg pens, to inform them of the recall information contained within this alert. Additional advice has also been provided for patients with Emerade 300mcg pens and Emerade 500mcg pens, which are not currently subject to a recall due to insufficient supplies of alternative brands of pens.  Specific letters for patients have also been produced.


No further supplies of Emerade will be available on the UK market until the issue has been resolved, therefore patients and carers should be appropriately trained to use other brands.


Medicines and Healthcare products Regulatory Agency

Resource links:

Emerade 150mcg Patient Letter

Emerade 300mcg-500mcg Patient Letter